Hematological Cancers

If you or a loved one have been diagnosed with an aggressive blood cancer, a clinical trial studying the potential of a new targeted treatment could be an option. Continue reading to learn more about two ongoing trials and see if you are eligible to enroll.


Cancer is caused by changes to specific genes that control how our cells grow and divide. Some cancers are characterized by increased activity of a protein called Positive Transcription Elongation Factor B (P-TEFb). P-TEFb plays a central role in helping cancer cells survive and thrive by increasing levels of specific genes. MYC and BCL2 are some of these genes.

Increased MYC is estimated to be involved in over 70% of cancers1 . If you aren’t sure if MYC is involved in your or your loved one’s cancer, ask your doctor. He or she can help get genetic testing completed to better understand your cancer.

1Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22-35. doi:10.1016/j.cell.2012.03.003

About the Phase 1 Clinical Trial of Enitociclib

Enitociclib (aka VIP152) is a P-TEFb inhibitor, meaning it works to block the activity of P-TEFb. Blocking P-TEFb stops a series of signals that can lead to tumor growth, and, as a result, treatment with enitociclib is expected to decrease the production of cancer-promoting genes, such as MYC and MCL1. For patients whose cancers are driven by MYC, blocking P-TEFb at the beginning of the pathway which drives cancer growth may be a way to slow or stop tumor growth and disease progression.

Tumor Growth & Progression

Controls Tumor Growth & Progression in Preclinal Studies

There are currently two clinical trials underway studying enitociclib in aggressive blood cancers. The trial that you may qualify for depends on the specific type of blood cancer you have, and its specific characteristics.

Eligibility for Trial A

Double-hit diffuse large B-cell lymphoma

Eligibility for Trial B

Chronic lymphocytic leukemia


Study Locations

Contact us to learn more